Pregabalin Capsule
Product Images NDC 72603-356

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72603-356). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalincapsules100mgcontainerlabel (Pregabalincapsules100mgcontainerlabel)

Label for Pregabalin Capsules 100 mg by NorthStar RxLLC, containing 90 capsules. The label includes dosage information, storage instructions, a barcode, and manufacturing details indicating production by Hetero Labs Limited in India for Northstar Rx LLC, Memphis, TN.*

FDA Label Image

Pregabalincapsules150mgcontainerlabel (Pregabalincapsules150mgcontainerlabel)

Pregabalin Capsules 150 mg oral capsules label from NorthStar Rx LLC. The package contains 90 capsules. The label includes storage instructions, dosage note, pharmacist dispensing guidance, and manufacturing details including Hetero Labs Limited in India. The label features a purple and white color scheme with a barcode and regulatory information.*

FDA Label Image

Pregabalincapsules200mgcontainerlabel (Pregabalincapsules200mgcontainerlabel)

Label for Pregabalin Capsules 200 mg, oral dosage form by NorthStar RxLLC. The label indicates 90 capsules per container with storage instructions, a pharmacist warning about medication guides, and manufacturing details by Hetero Labs Limited, India. The NDC code 72603-357-01 is shown along with a barcode.*

FDA Label Image

Pregabalincapsules25mgcontainerlabel (Pregabalincapsules25mgcontainerlabel)

Label for Pregabalin Capsules 25 mg, oral dosage form, supplied by NorthStar RxLLC. The label includes the NDC 72603-352-01 and indicates a package size of 90 capsules. It provides storage instructions (20° to 25°C), dispensing guidance, and cautions to keep out of children's reach. Manufactured by Hetero Labs Limited, India, for NorthStar Rx LLC, Memphis, TN.*

FDA Label Image

Pregabalincapsules300mgcontainerlabel (Pregabalincapsules300mgcontainerlabel)

Label for Pregabalin Capsules 300 mg by NorthStar RxLLC. The label shows a 90-capsule package with instructions for usual dosage reference and storage at 20° to 25°C. It includes a caution to keep capsules out of children's reach, a barcode, and manufacturing details including NorthStar Rx LLC and Hetero Labs Limited in India.*

FDA Label Image

Pregabalincapsules50mgcontainerlabel (Pregabalincapsules50mgcontainerlabel)

Label for Pregabalin Capsules 50 mg by NorthStar RxLLC, containing 90 capsules. The label includes storage instructions, a barcode, and manufacturing details showing production by Hetero Labs Limited in India. It also highlights the requirement to dispense a Medication Guide with the product.*

FDA Label Image

Pregabalincapsules75mgcontainerlabel (Pregabalincapsules75mgcontainerlabel)

Pregabalin Capsules 75 mg oral dosage form label from NorthStar RxLLC. The label indicates 90 capsules in the container. It includes storage instructions, a pharmacist note about a medication guide, manufacturer details including Hetero Labs Limited in India, and a barcode. The label notes the product is for prescription use only.*

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. Four groups are compared: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The graph illustrates the effectiveness of these dosages in improving patient pain levels over a range of improvement percentages.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A Kaplan-Meier survival curve chart comparing Pregabalin and placebo groups. The vertical axis represents the estimated percentage of subjects without LTR (loss to response), ranging from 0% to 100%. The horizontal axis shows time in days, spanning from 0 to 180 days. Solid and dashed lines represent Pregabalin and placebo groups, respectively, depicting differences in the proportion of subjects without LTR over time.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line graph comparing the percent of subjects improved over time from baseline to Week 12 using the ROCF measure. It features two lines, one solid line representing Pregabalin and a dashed line representing Placebo, plotted against percent improved on the vertical axis and ROCF percent improved from baseline on the horizontal axis.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line graph comparing the percent of subjects improved from baseline to Week 16 BOCF between Pregabalin and Placebo groups. The x-axis represents the percent improved, ranging from 0 to 100%, and the y-axis shows the percent of subjects improved from 0 to 100%. The graph includes two lines: a solid line for Pregabalin and a dotted line for Placebo, illustrating greater improvement with Pregabalin.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line graph comparing the percent improvement in pain from baseline against the percent of patients improved. It features two lines representing Pregabalin 100 mg taken three times a day versus placebo, showing higher patient improvement with Pregabalin over the range of pain improvement percentages.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph depicting the percentage of patients improved plotted against the percent improvement in pain from baseline for Pregabalin oral capsules at doses of 75 mg, 150 mg, and 300 mg taken two times a day, compared with placebo. The graph shows trends across varying levels of pain improvement.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The vertical axis shows percent of patients improved, and the horizontal axis shows percent improvement in pain from baseline.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line graph displaying the percent of patients improved against the percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and a placebo, with two vertical reference lines at 30% and 50% improvement.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

A bar chart comparing responder rates (%) across different dosages of Pregabalin and placebo in two clinical studies, Study E1 and Study E3. The x-axis shows treatment groups with doses and frequency (BID or TID), and the y-axis shows responder rates from 0% to 60%. Percentages for each group are displayed atop bars, with an asterisk indicating statistical significance versus placebo.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A dose-response line graph depicting seizure reduction as median percentage change from baseline across different doses of pregabalin (mg/day) up to 600 mg/day. Four studies (E1 BD, E2 TID, E3 BD, E3 TID) are represented using distinct markers, showing increased seizure reduction with higher doses. Significant p-values (≤ 0.0001 or 0.0007) are noted at various doses. Placebo dose is indicated at zero mg/day.*

FDA Label Image

Pregabalinfigure8 (Pregabalinfigure8)

A vertical bar chart depicting responder rates (%) for Pregabalin at doses of 2.5 mg/kg/day and 10 mg/kg/day compared to placebo. The chart shows responder rates of 22.6% for placebo (N=93), 29.1% for 2.5 mg/kg/day (N=103), and 40.6% for 10 mg/kg/day (N=96). The y-axis represents responder rate percentage, and the x-axis categorizes the groups.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline, showing curves for Pregabalin at 600 mg, 450 mg, and 300 mg daily doses compared to placebo. The graph illustrates the distribution of patient responses across different levels of pain improvement.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure of Pregabalin, showing its molecular formula with an amino group, carboxyl group, and a branched hydrocarbon chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.